GreyBird Portfolio Companies: Angstrom Bio

The Clinical Problem

Despite tremendous progress made in diagnostics, testing SARS-CoV-2 and other respiratory pathogens remains an area plagued by too many tradeoffs between availability, accuracy and speed, not to mention ease of sample collection, cost and adaptability.  An accurate, rapid, scalable and low cost molecular diagnostic test that is readily adaptable to a wide range of targets has the opportunity to revolutionize the industry.

The Angstrom Solution

Angstrom’s AMPD diagnostics platform combines novel nucleotide chemistry with advanced machine learning to leverage the extreme resolution and bandwidth of nanopore Third Generation Sequencing and thereby enable population-scale molecular diagnostics with unprecedented throughput, high sensitivity and scale-enabling cost.  Initially implemented as a rapid SARS-CoV-2 diagnostic, AMPD provides the ability to rapidly incorporate additional targets without sacrificing throughput or accuracy, and without materially increasing costs.  The test is performed using saliva rather than nasopharyngeal swabs and the platform is capable of providing hundreds, to hundreds of thousands of diagnostic results per day, with diagnostic assays that can discriminate from among large numbers of diagnostic targets with best-in-class accuracy, and at a fraction of the cost of current qPCR diagnostics.

The Business Plan

AMPD will initially be deployed for SARS-CoV-2 diagnostics in a CLIA high-complexity lab in Austin, Texas.  Angstrom has plans in place to develop a multi-pathogen respiratory syndromic panel, which will initially include influenza A & B, as well as parainfluenza and RSV.  Looking beyond respiratory viruses, AMPDä, can easily be seen as a platform for massively parallel, high sensitivity, low cost detection of a wide range of targets.  The potential market for these tests, particularly at the scale and cost that AMPDä allows, is massive.

Latest News from Angstrom Bio

Angstrom Bio Raises $3M in Private Financing